{"nctId":"NCT02105701","briefTitle":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","startDateStruct":{"date":"2014-06-05","type":"ACTUAL"},"conditions":["Hepatitis C Infection"],"count":420,"armGroups":[{"label":"Grazoprevir + Elbasvir 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Grazoprevir + Elbasvir"]},{"label":"Grazoprevir + Elbasvir + RBV 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Grazoprevir + Elbasvir","Drug: Ribavirin"]},{"label":"Grazoprevir + Elbasvir 16 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Grazoprevir + Elbasvir"]},{"label":"Grazoprevir + Elbasvir + RBV 16 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Grazoprevir + Elbasvir","Drug: Ribavirin"]}],"interventions":[{"name":"Grazoprevir + Elbasvir","otherNames":["MK-5172A"]},{"name":"Ribavirin","otherNames":["Rebetol®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented chronic HCV GT1, GT4, or GT6 with no evidence of non-typable or mixed genotype infection (positive for anti-HCV antibody, HCV ribonucleic acid \\[RNA\\], or any of the listed GTs at least 6 months prior to screening must be confirmed by screening lab results)\n* Cirrhosis defined as liver biopsy showing METAVIR F4; or Fibroscan showing result \\>12.5 kilopascals (kPa); or FibroSure® (Fibrotest®) score of \\>0.75 and an aspartate aminotransferase (AST):platelet ratio index (APRI) of \\>2\n* Absence of cirrhosis defined as liver biopsy showing absence of cirrhosis; or Fibroscan result of ≤ 12.5 kPa; or Fibrosure® (Fibrotest®) score of ≤ 0.48 and APRI ≤ 1\n* Previous HCV treatment status of peginterferon/RBV Null responder; or peginterferon/RBV Partial responder; or peginterferon/RBV Treatment Relapse\n* For human immunodeficiency virus (HIV) co-infected participants: documented HIV-1 infection; currently naïve to treatment with any antiretroviral therapy (ART) and have no plans to initiate ART treatment while participating in this study; or be on HIV ART for at least 8 weeks prior to study entry (dual nucleoside reverse transcriptase inhibitor \\[NRTI\\] backbone of tenofovir or abacavir and either emtricitabine or lamivudine plus raltegravir (or dolutegravir or rilpivirine) (no changes in HIV regimen allowed within 4 weeks of randomization); cluster of differentiation 4 (CD4)+ T-cell count \\>200 cells/mm\\^3 at screening; documented undetectable plasma HIV-1 RNA at least 8 weeks prior to screening; participants not on ART, HIV RNA must be \\<50,000 copies/mL; must have at least one viable antiretroviral regimen alternative beyond their current regimen in the event of HIV virologic failure and the development of antiretroviral drug resistance\n* Agree to use two acceptable methods of birth control from at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations; a male participant who is not (or whose partner is not) of reproductive potential is eligible without requiring the use of contraception\n\nExclusion Criteria:\n\n* Evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease\n* For participants with cirrhosis, participants who are Child-Pugh Class B or C or who have a Pugh-Turcotte (CPT) score \\>6, must be excluded\n* Co-infected with hepatitis B virus\n* Has had previous direct-acting antiviral treatment\n* History of malignancy \\<=5 years prior except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy\n* Has cirrhosis and liver imaging showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC\n* Taking or plans to take any HIV therapy that includes a ritonavir-boosted or unboosted protease inhibitor, efavirenz or etravirine\n* Currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another such study during the course of this study\n* Clinically-relevant drug or alcohol abuse within 12 months\n* Pregnant, breast-feeding, or expecting to conceive or donate eggs or sperm from Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations; or is a male whose female partner(s) is/are pregnant\n* History of organ transplant (including hematopoietic stem cell transplants) other than cornea and hair\n* Poor venous access\n* History of gastric surgery (e.g., stapling, bypass) or history of malabsorption disorders (e.g., celiac sprue disease)\n* Hemoglobinopathy, including, but not limited to, thalassemia major\n* Any medical condition requiring, or likely to require, chronic systemic corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppressant drugs during the course of the trial\n* For participants with HIV, history of opportunistic infection in the preceding 6 months\n* For participants with HIV, use of HIV drugs other than a dual NRTI backbone of tenofovir or abacavir and either emtricitabine or lamivudine plus raltegravir (or dolutegravir or rilpivirine)\n* Evidence or history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)","description":"HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"94.2","spread":null},{"groupId":"OG002","value":"92.4","spread":null},{"groupId":"OG003","value":"98.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AE)","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"95","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Treatment Due to an AE","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Undetectable HCV RNA 24 Weeks After the End of All Treatment (SVR24)","description":"HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.4","spread":null},{"groupId":"OG001","value":"94.2","spread":null},{"groupId":"OG002","value":"89.5","spread":null},{"groupId":"OG003","value":"95.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":105},"commonTop":["Fatigue","Headache","Nausea","Asthenia","Accidental overdose"]}}}